Effects of Tamsulosin, Solifenacin, and Combination Therapy for the Treatment of Ureteral Stent Related Discomforts.
10.4111/kju.2011.52.7.485
- Author:
Kyoung Taek LIM
1
;
Yong Tae KIM
;
Tchun Yong LEE
;
Sung Yul PARK
Author Information
1. Department of Urology, Hangyang University College of Medicine, Seoul, Korea. syparkuro@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Pain;
Stents;
Ureter
- MeSH:
Humans;
Lower Urinary Tract Symptoms;
Pain Measurement;
Polyurethanes;
Prostate;
Quinuclidines;
Stents;
Sulfonamides;
Tetrahydroisoquinolines;
Ureter;
Ureteroscopy;
Urinary Calculi;
Solifenacin Succinate
- From:Korean Journal of Urology
2011;52(7):485-488
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the effect of tamsulosin, solifenacin, and combination therapy of two agents in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents. MATERIALS AND METHODS: A total of 168 patients underwent placement of a double-J ureteral stent after retrograde ureteroscopy for urinary stone disease. All patients received polyurethane double-J ureteral stents (6 Fr, 24 or 26 cm), which were removed a mean of 14 days postoperatively. A total of 48 patients were given no medication (Group 1), 43 patients were given tamsulosin 0.2 mg once daily (Group 2), 45 patients were given solifenacin 5 mg once daily (Group 3), and 32 patients were given a combination of two agents postoperatively (Group 4). International Prostate Symptom Score/quality of life (IPSS/QoL) and visual analogue pain scale (VAPS) questionnaires were completed by each patient at 1 day postoperatively and on the day of stent removal. RESULTS: In the total group of patients, the mean age was 50.24+/-12.90 years. There was a significant difference in the IPSS total score between group 1 and groups 3 and 4. Group 4 also differed significantly from group 1 in the irritative subscore. The obstructive subscore differed between groups 2 and 4 and group 1. There was a statistically significant difference between group 1 and group 4 in the QoL score. There were no significant differences in the VAPS. CONCLUSIONS: Combination therapy with tamsulosin and solifenacin improved both irritative and obstructive symptoms more than in the other groups. Combination therapy should be strongly considered for patients who complain of stent-related symptoms.
